Uncategorized

China’s First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351

Innovent Biologics, Inc. announces that the New Drug Application for IBI351 has been accepted by the Center for Drug Evaluation of the National Medical Products Administration of China and granted Priority Review designation[1], for the treatment of patients with advanced non-small cell lung cancer harboring KRAS G12C mutation who have received at least one systemic

China’s First NDA for a KRAS G12C Inhibitor: Innovent Announces the National Medical Products Administration of China Has Accepted and Granted Priority Review Designation to the New Drug Application for IBI351 Read More »

Scroll to Top